"It is too early to fully assess the therapy's effectiveness and...

"It is too early to fully assess the therapy's effectiveness and is expensive and time-consuming."

"The idea of the therapy is to boost levels of these cancer-spotting T-cells. It has to be tailored to each patient as each tumour is unique."

Just the above 2 points makes it inferior to CF33 which attacks all cancer and not time-consuming. I don't know if it is going to be expensive or not yet although by all account, it will certainly be far cheaper than anything that needs tailoring to individual patients.

Still the fact that it again relies on waking up the patients own immune system is another confirmation that IMU's is on the right track from the word go with its B-cell and now CF33 platforms.